Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer

Authors :: Ferry A.L.M. Eskens
Yasuhide Yamada
Jason E. Faris
Takayuki Yoshino
Jean-Pierre Delord
Robin M.J.M. van Geel
Martin Schuler
Peijuan Zhu
Elena Elez
René Bernards
Emin Avsar
Anna Spreafico
Johanna C. Bendell
Josep Tabernero
Tim Demuth
Zev A. Wainberg
Arkendu Chatterjee
Martijn P. Lolkema
Jan H.M. Schellens
Petr Kavan
Source :: Journal of Clinical Oncology. 32:3514-3514
Publication Year :: 2014
Publisher :: American Society of Clinical Oncology (ASCO), 2014.
Abstract: 3514 Background: In contrast to BRAFV600 mutated (BRAFm) advanced melanoma, BRAFm colorectal carcinoma (CRC) does not respond to BRAF inhibitors due to strong feedback activation of the epidermal g...

Full Text Access

Tools